Pyrazinamide

also known as PZA · .alpha.-pyrazinamide · Aldinamid · Aldinamide · Eprazin · Farmizina · Isopas · MK-56 · +19 more

Developed for: pulmonary tuberculosis · tuberculosis · HIV infectious disease · multidrug-resistant tuberculosis · meningeal tuberculosis · rifampicin-resistant tuberculosis · extensively drug-resistant tuberculosis · anterior uveitis
+3 more
· ocular tuberculosis · tuberculosis, spinal · drug-resistant tuberculosis
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · Huashan Hospital · Global Alliance for TB Drug Development · Beijing Chest Hospital · Radboud University Medical Center · Shanghai Pulmonary Hospital, Shanghai, China
+204 more
· University College, London · Centers for Disease Control and Prevention · European and Developing Countries Clinical Trials Partnership (EDCTP) · Seoul National University Hospital · TASK Applied Science · Tuberculosis Research Centre, India · ANRS, Emerging Infectious Diseases · Anhui Chest Hospital · Chengdu Public Health Clinical Center · First Affiliated Hospital of Zhejiang University · GlaxoSmithKline · Institute of Tropical Medicine, Belgium · International Tuberculosis Research Center · Korean Center for Disease Control and Prevention · London School of Hygiene and Tropical Medicine · Makerere University · Michael Hoelscher · National University Hospital, Singapore · Shanghai Public Health Clinical Center · Sociedad Andaluza de Enfermedades Infecciosas · University of California, San Francisco · University of Oxford · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · All India Institute of Medical Sciences · All India Institute of Medical Sciences, Jodhpur · Asan Medical Center · Asian Medical Center · Assistance Publique - Hôpitaux de Paris · Aurum Institute · Barcelona Institute for Global Health · Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · Beijing Chest Hospital, Capital Medical University · Beijing Ditan Hospital · Beijing Municipal Science & Technology Commission · Beijing Research Institute for Tuberculosis Control · Beijing YouAn Hospital · Biomedical Research and Training Institute, Zimbabwe · Boston University · Brighton & Sussex Medical School · Centre Hospitalier Cocody · Centre for Tuberculosis Control of Guangdong Province · Centre for the AIDS Programme of Research in South Africa · Changchun Infectious Disease Hospital · Chest Hospital of Guangxi Zhuang Autonomous Region · Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC · Chongqing Infectious Disease Medical Center · Chongqing Public Health Medical Center · Christian Medical College, Vellore, India · Critical Path Institute · Dankook University · David Boulware · Desmond Tutu TB Centre · Doctors Without Borders · Eduardo Mondlane University · Epicentre · European Lung Foundation · European Respiratory Society · European Union · Faculty of Medicine, University of Indonesia · Find · First Affiliated Hospital of Xinjiang Medical University · Foundation for Innovative New Diagnostics, Switzerland · Fourth Taiyuan People's Hospital, China · French National Institute of Health and Medical Research · Ganzhou Fifth People's Hospital, China · Gates Medical Research Institute · German Center for Infection Research · German Federal Ministry of Education and Research · Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control · Guangzhou National Laboratory · Guangzhou eighth People's Hospital ,Guangzhou Medilcal University · Guiyang Public Health Clinical Center · Guizhou Aerospace Hospital · Harbin Chest Hospital · all 210 on the full record

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	PYRAZINAMIDE	—	1971-06-03	fda.gov ↗

Trials 73 · started per year

today

US approved 1971

197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 16 trials · 1 missed
Phase 1	NCT02700347	Feb → Apr 2016	tuberculosis	National University Hospital, Singapore	Completed	Missed primary
Phase 1	NCT02602509	Nov 2015 → Feb 2016	tuberculosis	National University Hospital, Singapore	Completed	No outcome recorded
Phase 1	NCT02457208	Jul 2015 → Jan 2018	tuberculosis	University of Oxford	Completed	No outcome recorded
Phase 1	NCT02128308	Nov → Dec 2013	—	Seoul National University Hospital	Completed	No outcome recorded
Phase 1	NCT00990990	Oct 2009 → May 2010	tuberculosis	Sequella, Inc.	Completed	No outcome recorded
Phase 1	NCT00816426	Dec 2008 → Aug 2014	tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT04044001	Nov 2019 → Mar 2022	pulmonary tuberculosis	Michael Hoelscher	Completed	No outcome recorded
Phase 219 trials · 4 met primary · 1 missed
Phase 2	NCT07467252	Sep 2026 → Dec 2027 expected	pulmonary tuberculosis	Ministry of Health, Saudi Arabia	Not yet recruiting	No outcome recorded
Phase 2	NCT07227779	Jul 2026 → Mar 2028 expected	HIV infectious disease, meningeal tuberculosis	David Boulware	Recruiting	No outcome recorded
Phase 2	NCT07129629	Aug 2025 → Dec 2026 expected	pulmonary tuberculosis	Shanghai Pulmonary Hospital, Shanghai, China	Not yet recruiting	No outcome recorded
Phase 2	NCT06748937	Mar 2025 → Mar 2026 overdue	pulmonary tuberculosis	TASK Applied Science	Recruiting	No outcome recorded
Phase 2	NCT06114628	Jan 2024 → Feb 2027 expected	pulmonary tuberculosis	University College, London	Recruiting	No outcome recorded
Phase 2	NCT05383742	Dec 2023 → Apr 2028 expected	meningeal tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 2	NCT06041919	Sep 2023 → Jul 2024	pulmonary tuberculosis	Thirty Respiratory Limited	Terminated	No outcome recorded
Phase 2	NCT05971602	Jul 2023 → Feb 2025	pulmonary tuberculosis	Gates Medical Research Institute	Terminated	No outcome recorded
Phase 2	NCT05807399	Apr 2023 → Oct 2027 expected	pulmonary tuberculosis	Michael Hoelscher	Recruiting	No outcome recorded
Phase 2	NCT04694586	Nov 2022 → May 2024	pulmonary tuberculosis	University Hospital, Linkoeping	Suspended	No outcome recorded Stop: Enrollment
Phase 2	NCT04311502	Nov 2021 → Jun 2024	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	Missed primary Stop: Enrollment
Phase 2	NCT05005637	Aug 2021 → Oct 2024	ocular tuberculosis	Faculty of Medicine, University of Indonesia	Completed	Met primary
Phase 2	NCT04629378	Aug 2020 → Jun 2021	tuberculosis	TASK Applied Science	Completed	No outcome recorded
Phase 2	NCT02821832	Jun 2017 → Oct 2021	pulmonary tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT02619994	Jan 2016 → Jun 2021	multidrug-resistant tuberculosis	Seoul National University Hospital	Completed	Met primary
Phase 2	NCT02371681	Feb 2015 → Sep 2017	pulmonary tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT02193776	Oct 2014 → Feb 2016	tuberculosis	Global Alliance for TB Drug Development	Completed	Met primary
Phase 2	NCT01691534	Oct 2012 → Apr 2013	pulmonary tuberculosis	Global Alliance for TB Drug Development	Completed	No outcome recorded
Phase 2	NCT01498419	Mar 2012 → Apr 2013	pulmonary tuberculosis	Global Alliance for TB Drug Development	Completed	Met primary

Phase 2/35 trials · 2 met primary · 1 missed
Phase 2/3	NCT05766267	Nov 2023 → Dec 2026 expected	pulmonary tuberculosis	Centers for Disease Control and Prevention	Active not recruiting	No outcome recorded
Phase 2/3	NCT05401071	Jan 2023 → Oct 2024 overdue	pulmonary tuberculosis	Huashan Hospital	Recruiting	No outcome recorded
Phase 2/3	NCT03915366	Mar 2020 → Jan 2025	HIV infectious disease, cytomegalovirus infection, pneumonia, tuberculosis	Hospital Universitario 12 de Octubre	Completed	Missed primary
Phase 2/3	NCT03338621	Jul 2018 → Jul 2021	multidrug-resistant tuberculosis, pulmonary tuberculosis	Global Alliance for TB Drug Development	Completed	Met primary
Phase 2/3	NCT02454205	Nov 2015 → Dec 2020	extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis	University of Cape Town	Completed	Met primary
Phase 319 trials · 2 met primary · 3 missed
Phase 3	NCT07675954	Oct 2026 → Jun 2032 expected	rifampicin-resistant tuberculosis	Seoul National University Hospital	Not yet recruiting	No outcome recorded
Phase 3	NCT07268664	Dec 2025 → May 2028 expected	pulmonary tuberculosis, rifampicin-resistant tuberculosis	Beijing Chest Hospital	Not yet recruiting	No outcome recorded
Phase 3	NCT07163143	Nov 2025 → Nov 2028 expected	tuberculosis	University College, London	Not yet recruiting	No outcome recorded
Phase 3	NCT06905522	Jun 2025 → Jan 2029 expected	pulmonary tuberculosis	Shenzhen Third People's Hospital	Recruiting	No outcome recorded
Phase 3	NCT05917340	Mar 2024 → Sep 2027 expected	meningeal tuberculosis	Indian Council of Medical Research	Not yet recruiting	No outcome recorded
Phase 3	NCT05454345	Oct 2022 → Jun 2025	pulmonary tuberculosis	First Affiliated Hospital of Zhejiang University	Unknown	No outcome recorded
Phase 3	NCT05081401	May 2022 → Dec 2026 expected	extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis	Huashan Hospital	Recruiting	No outcome recorded
Phase 3	NCT04738812	Apr 2022 → Nov 2025	HIV infectious disease, immunodeficiency disease, tuberculosis	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 3	NCT04117698	Nov 2019 → May 2023	anterior uveitis	Assistance Publique - Hôpitaux de Paris	Unknown	No outcome recorded
Phase 3	NCT02975570	Aug 2017 → Aug 2021	multidrug-resistant tuberculosis	Boston University	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT02754765	Dec 2016 → Jun 2023	multidrug-resistant tuberculosis, pulmonary tuberculosis	Doctors Without Borders	Completed	Mixed
Phase 3	NCT02409290	Mar 2016 → May 2022	multidrug-resistant tuberculosis	IUATLD, Inc	Completed	Met primary
Phase 3	NCT02342886	Feb 2015 → Jan 2018	multidrug-resistant tuberculosis, pulmonary tuberculosis	Global Alliance for TB Drug Development	Completed	No outcome recorded
Phase 3	NCT01154959	Feb 2010 → Dec 2015	pulmonary tuberculosis	Tuberculosis Research Centre, India	Completed	No outcome recorded
Phase 3	NCT00933790	Sep 2009 → Dec 2016	HIV infectious disease, pulmonary tuberculosis	Tuberculosis Research Centre, India	Completed	Met primary
Phase 3	NCT00864383	Jan 2008 → Oct 2013	pulmonary tuberculosis	Global Alliance for TB Drug Development	Completed	Missed primary
Phase 3	NCT00317330	Dec 2004 → Jun 2005	tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00130247	Apr 2002 → Sep 2008	tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00376012	Feb 2001 → Sep 2007	HIV infectious disease, tuberculosis	Tuberculosis Research Centre, India	Unknown	Missed primary

Phase 416 trials · 4 missed
Phase 4	NCT06153069	Nov 2025 → Nov 2027 expected	tuberculosis	Huashan Hospital	Recruiting	No outcome recorded
Phase 4	NCT05278988	Apr 2021 → Oct 2024	multidrug-resistant tuberculosis	Shanghai Pulmonary Hospital, Shanghai, China	Completed	No outcome recorded
Phase 4	NCT03867136	Jun 2020 → Aug 2024	multidrug-resistant tuberculosis	Huashan Hospital	Completed	No outcome recorded
Phase 4	NCT03830671	Mar 2019 → Jun 2022	multidrug-resistant tuberculosis	Beijing Chest Hospital	Completed	No outcome recorded
Phase 4	NCT03237182	Jun 2017 → Dec 2022	multidrug-resistant tuberculosis	Centre for the AIDS Programme of Research in South Africa	Terminated	No outcome recorded
Phase 4	NCT02901288	Aug 2016 → Dec 2018	pulmonary tuberculosis	Beijing Chest Hospital	Unknown	No outcome recorded
Phase 4	NCT02477852	Apr 2015 → Dec 2017	tuberculosis, spinal	Beijing Chest Hospital	Unknown	No outcome recorded
Phase 4	NCT02057796	Sep 2014 → Apr 2018	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	Missed primary
Phase 4	NCT02331823	Jun 2013 → Dec 2015	pulmonary tuberculosis	Shanghai Pulmonary Hospital, Shanghai, China	Unknown	No outcome recorded
Phase 4	NCT01782950	Feb 2013 → Mar 2016	tuberculosis	Makerere University	Unknown	No outcome recorded
Phase 4	NCT01380080	Oct 2011 → Jan 2015	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	Missed primary
Phase 4	NCT01395654	Jul 2011 → Dec 2013	hepatitis, pulmonary tuberculosis	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 4	NCT00405301	Dec 2006 → Jun 2008	drug-induced liver injury, tuberculosis	All India Institute of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT00216333	Dec 2003 → Jun 2007	tuberculosis	International Union Against Tuberculosis and Lung Diseases	Unknown	Missed primary
Phase 4	NCT00402454	Jan 1994 → Dec 1998	HIV infectious disease	Sociedad Andaluza de Enfermedades Infecciosas	Completed	No outcome recorded
Phase 4	NCT00402610	Jan 1994 → Dec 1998	HIV infectious disease, tuberculosis	Sociedad Andaluza de Enfermedades Infecciosas	Completed	Missed primary

Phase not applicable7 trials
—	NCT07608172	May 2026 → Jun 2028 expected	pulmonary tuberculosis	Shanghai Public Health Clinical Center	Not yet recruiting	No outcome recorded
—	NCT04717908	Jan 2021 → Jun 2024	multidrug-resistant tuberculosis	Huashan Hospital	Completed	No outcome recorded
—	NCT00023374	Aug 2000 → Dec 2006	tuberculosis	Centers for Disease Control and Prevention	Completed	No outcome recorded
—	NCT00000950	? → May 2002	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000636	? → Oct 1997	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000638	? → Sep 1999	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000796	? → Oct 1998	HIV infectious disease, pulmonary tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Comparator or background therapy67 trials
Phase 0	NCT02099240 Comparator	Mar 2014 → Nov 2018	osteomyelitis	University of Louisville	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT00004736 Background	—	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT03678688 Comparator	Oct 2018 → Feb 2022	pulmonary tuberculosis	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	Missed primary
Phase 1/2	NCT02958709 Background	Feb 2017 → Nov 2020	meningeal tuberculosis	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT07656012 Background	Oct 2026 → Sep 2030 expected	tuberculosis	University of Wisconsin, Madison	Not yet recruiting	No outcome recorded
Phase 2	NCT07773610 Comparator	Sep 2026 → Dec 2027 expected	pulmonary tuberculosis	TASK Applied Science	Not yet recruiting	No outcome recorded
Phase 2	NCT07595042 Background	Jul 2026 → Jun 2029 expected	tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Not yet recruiting	No outcome recorded
Phase 2	NCT07350174 Comparator	Mar 2026 → Mar 2028 expected	meningeal tuberculosis	BioVersys AG	Not yet recruiting	No outcome recorded
Phase 2	NCT07073638 Background	Oct 2025 → Sep 2026 overdue	pulmonary tuberculosis	Thirty Respiratory Limited	Recruiting	No outcome recorded
Phase 2	NCT06446245 Background	Aug 2025 → Nov 2027 expected	meningeal tuberculosis	National University Hospital, Singapore	Recruiting	No outcome recorded
Phase 2	NCT06917495 Background	Apr 2025 → Dec 2027 expected	tuberculosis, spinal	Shandong University	Not yet recruiting	No outcome recorded
Phase 2	NCT06192160 Comparator	Mar 2025 → Nov 2026 expected	pulmonary tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 2	NCT05630872 Background	Feb 2024 → May 2025	tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT06199921 Comparator	Jan 2024 → Mar 2026 overdue	pulmonary tuberculosis	Obafemi Awolowo University Teaching Hospital	Recruiting	No outcome recorded
Phase 2	NCT05556746 Comparator	Nov 2023 → Jun 2025 overdue	HIV infectious disease, pulmonary tuberculosis	Brigham and Women's Hospital	Active not recruiting	No outcome recorded
Phase 2	NCT06058299 Comparator	Oct 2023 → Dec 2024 overdue	pulmonary tuberculosis	Global Alliance for TB Drug Development	Active not recruiting	No outcome recorded
Phase 2	NCT06224036 Comparator	Oct 2023 → Mar 2024	drug-resistant tuberculosis	Beijing Chest Hospital	Unknown	Met primary
Phase 2	NCT05534750 Comparator	Apr 2023 → Apr 2026 overdue	multidrug-resistant tuberculosis	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 2	NCT04179500 Background	Sep 2021 → Jun 2023	multidrug-resistant tuberculosis, pulmonary tuberculosis	Global Alliance for TB Drug Development	Completed	No outcome recorded
Phase 2	NCT04930744 Background	Aug 2021 → Apr 2025	coinfection, pulmonary tuberculosis	University of Massachusetts, Worcester	Completed	No outcome recorded
Phase 2	NCT04504851 Background	Aug 2020 → Mar 2021	pulmonary tuberculosis	National University Hospital, Singapore	Unknown	Missed primary
Phase 2	NCT04176250 Comparator	Jan 2020 → Oct 2022	pulmonary tuberculosis	Gates Medical Research Institute	Completed	No outcome recorded
Phase 2	NCT03927313 Background	Jun 2019 → Mar 2021	HIV infectious disease, meningeal tuberculosis	University of Cape Town	Completed	No outcome recorded
Phase 2	NCT03563599 Comparator	Jul 2018 → Sep 2019	tuberculosis	Qurient Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT02836483 Comparator	Dec 2016 → Jul 2019	pulmonary tuberculosis	LigaChem Biosciences, Inc.	Completed	No outcome recorded
Phase 2	NCT03281226 Comparator	Dec 2016 → Jun 2019	AIDS, pulmonary tuberculosis	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	Unknown	No outcome recorded
Phase 2	NCT01589497 Comparator	Jun 2015 → Jan 2016	tuberculosis	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 2	NCT02256696 Background	Apr 2015 → May 2022	pulmonary tuberculosis	Johns Hopkins University	Completed	Mixed
Phase 2	NCT02365623 Background	Feb 2015 → Nov 2018	multidrug-resistant tuberculosis	Janssen Pharmaceutical K.K.	Completed	No outcome recorded
Phase 2	NCT02279875 Comparator	Nov 2014 → Nov 2016	pulmonary tuberculosis	Global Alliance for TB Drug Development	Completed	No outcome recorded
Phase 2	NCT01601626 Background	Jul 2013 → Jan 2017	HIV infectious disease, tuberculosis	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Terminated	No outcome recorded
Phase 2	NCT02121314 Comparator	Jul 2013 → Apr 2014	tuberculosis	University Medical Center Groningen	Completed	No outcome recorded
Phase 2	NCT01785186 Background	Apr 2013 → Sep 2014	pulmonary tuberculosis	Michael Hoelscher	Completed	Met primary
Phase 2	NCT01516203 Comparator	Dec 2012 → Dec 2013	tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 2	NCT01225640 Comparator	Aug → Dec 2011	tuberculosis	Sequella, Inc.	Completed	No outcome recorded
Phase 2	NCT01215851 Comparator	Oct 2010 → May 2011	pulmonary tuberculosis	Global Alliance for TB Drug Development	Completed	Met primary
Phase 2	NCT00728507 Background	Nov 2009 → Apr 2013	tuberculosis	Johns Hopkins University	Terminated	Missed primary Stop: Business
Phase 2	NCT00144417 Background	Feb 2006 → Jun 2007	tuberculosis	Centers for Disease Control and Prevention	Completed	Missed primary
Phase 2	NCT00140309 Background	Jul 2003 → Dec 2005	pulmonary tuberculosis	Centers for Disease Control and Prevention	Completed	Missed primary
Phase 2/3	NCT04721795 Comparator	Jan 2021 → Mar 2022	pulmonary tuberculosis	Obafemi Awolowo University Teaching Hospital	Completed	No outcome recorded
Phase 2/3	NCT03474198 Background	Mar 2018 → Jan 2022	pulmonary tuberculosis	University College, London	Completed	Mixed
Phase 2/3	NCT02169882 Background	Dec 2014 → Nov 2016	meningeal tuberculosis	Padjadjaran University	Completed	No outcome recorded
Phase 2/3	NCT02467608 Background	Dec 2012 → Jan 2019	pulmonary tuberculosis	Orient Pharma Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT07076225 Background	Jul 2025 → Jan 2030 expected	pulmonary tuberculosis	Shenzhen Third People's Hospital	Not yet recruiting	No outcome recorded
Phase 3	NCT06253715 Background	Jan 2025 → Sep 2027 expected	lymph node tuberculosis, pulmonary tuberculosis	Johns Hopkins University	Recruiting	No outcome recorded
Phase 3	NCT06727864 Background	Jan 2024 → Dec 2027 expected	pulmonary tuberculosis	Kaohsiung Veterans General Hospital.	Recruiting	No outcome recorded
Phase 3	NCT06081361 Comparator	Dec 2023 → Oct 2026 expected	pulmonary tuberculosis, rifampicin-resistant tuberculosis	Beijing Chest Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT04951986 Background	Aug 2021 → Dec 2025 overdue	HIV infectious disease, tuberculosis	University of Cape Town	Active not recruiting	No outcome recorded
Phase 3	NCT04260477 Comparator	Mar 2021 → Jun 2025 overdue	multidrug-resistant tuberculosis, pulmonary tuberculosis	Institute of Tropical Medicine, Belgium	Recruiting	No outcome recorded
Phase 3	NCT04145258 Background	Feb 2021 → Sep 2026 overdue	meningeal tuberculosis	ANRS, Emerging Infectious Diseases	Recruiting	No outcome recorded
Phase 3	NCT04485156 Background	Sep 2020 → Aug 2025 overdue	pulmonary tuberculosis	Seoul National University Hospital	Not yet recruiting	Missed primary
Phase 3	NCT04856644 Background	Jan 2020 → Dec 2023 overdue	pulmonary tuberculosis	Kaohsiung Veterans General Hospital.	Active not recruiting	No outcome recorded
Phase 3	NCT04062201 Comparator	Aug 2019 → Apr 2024	extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis	Wits Health Consortium (Pty) Ltd	Completed	No outcome recorded
Phase 3	NCT02581527 Background	Feb 2017 → Jan 2022	pulmonary tuberculosis	St George's, University of London	Completed	Missed primary
Phase 3	NCT02563327 Background	May 2016 → Aug 2021	tuberculosis	Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 3	NCT02153528 Background	Nov 2014 → Aug 2017	pulmonary tuberculosis	Damien Foundation	Completed	No outcome recorded
Phase 3	NCT02120638 Comparator	Apr 2014 → Apr 2016	multidrug-resistant tuberculosis	Huashan Hospital	Unknown	No outcome recorded
Phase 3	NCT00698334 Comparator	Apr 2006 → Sep 2010	AIDS, tuberculosis	All India Institute of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT06403943 Background	May 2023 → Oct 2026 expected	pulmonary tuberculosis	Beijing Chest Hospital	Recruiting	No outcome recorded
Phase 4	NCT05306223 Background	May 2022 → Aug 2025	multidrug-resistant tuberculosis	Beijing Chest Hospital	Unknown	Met primary
Phase 4	NCT03561753 Comparator	Dec 2017 → Dec 2019	pulmonary tuberculosis	Shanghai Pulmonary Hospital, Shanghai, China	Completed	No outcome recorded
Phase 4	NCT02231229 Comparator	Jul 2014 → Jul 2018	tuberculosis	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
—	NCT04187469 Comparator	Mar 2020 → Feb 2023	pulmonary tuberculosis	Fifth Affiliated Hospital, Sun Yat-Sen University	Unknown	No outcome recorded
—	NCT03604848 Comparator	Aug 2018 → Aug 2024	multidrug-resistant tuberculosis	Huashan Hospital	Unknown	No outcome recorded
—	NCT02554318 Background	Nov 2013 → Feb 2015	pulmonary tuberculosis	University of Giessen	Completed	No outcome recorded
—	NCT01677871 Comparator	Sep 2012 → Sep 2014	tuberculosis	Institute of Liver and Biliary Sciences, India	Unknown	No outcome recorded
—	NCT01344148 Background	Feb 2009 → Jun 2011	AIDS	Shanghai Public Health Clinical Center	Unknown	No outcome recorded

News releases announcing trial results or a regulatory action · 6

Date	Issuer	Release
2025-11-19	Global Alliance for TB Drug Development	Results Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time tballiance.org ↗ The 100 mg SPaL regimen had greater activity against TB than the standard of care HRZE (isoniazid, rifampin, pyrazinamide, and ethambutol), indicating the potential to shorten treatment time for active TB.
2019-11-13	Global Alliance for TB Drug Development	Results Results of Phase 2B Clinical Trial Testing New Drug-Resistant TB Treatment Published in Lancet Respiratory Medicine tballiance.org ↗ Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine.
2016-12-16	Global Alliance for TB Drug Development	Results Clinical Trial of BPaMZ Regimen Will Replace Phase 3 STAND Trial tballiance.org ↗ In light of these results, where the BPaMZ regimen appears to be much more promising compared to the PaMZ (pretomanid + moxifloxacin + pyrazinamide) regimen, the STAND trial testing the PaMZ regimen will not be reopened to new patients.
2015-03-18	Global Alliance for TB Drug Development	Results The Lancet: Results of Phase 2b Trial of Novel TB Regimen PaMZ Show Potential to Shorten, Improve TB Treatment tballiance.org ↗ Nearly twice (71 percent) as many TB patients treated with PaMZ had no TB in their sputum when cultured at the end of the 2-month course of the trial compared to patients treated with standard therapy (38 percent).
2015-01-29	Global Alliance for TB Drug Development	Results Phase 2a Published Results Show the Potential of a New TB Regimen with Novel Drugs Bedaquiline and Pretomanid (PA-824) tballiance.org ↗ Specifically, the BPaZ regimen killed more than 99 percent of TB bacteria in patient’s sputum in two weeks, and appeared well tolerated and safe.
2012-07-23	Global Alliance for TB Drug Development	Results Trial Signals Major Milestone in Hunt for New TB Drugs tballiance.org ↗ These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients.

All press releases naming this drug 6 releases

Date	Issuer	Release
2025-11-19	Global Alliance for TB Drug Development	Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time tballiance.org ↗
2019-11-13	Global Alliance for TB Drug Development	Results of Phase 2B Clinical Trial Testing New Drug-Resistant TB Treatment Published in Lancet Respiratory Medicine tballiance.org ↗
2016-12-16	Global Alliance for TB Drug Development	Clinical Trial of BPaMZ Regimen Will Replace Phase 3 STAND Trial tballiance.org ↗
2015-03-18	Global Alliance for TB Drug Development	The Lancet: Results of Phase 2b Trial of Novel TB Regimen PaMZ Show Potential to Shorten, Improve TB Treatment tballiance.org ↗
2015-01-29	Global Alliance for TB Drug Development	Phase 2a Published Results Show the Potential of a New TB Regimen with Novel Drugs Bedaquiline and Pretomanid (PA-824) tballiance.org ↗
2012-07-23	Global Alliance for TB Drug Development	Trial Signals Major Milestone in Hunt for New TB Drugs tballiance.org ↗

Evidence & citations 31 cited values

Every value below carries the sentence it was read from. 146 sources stand behind the page.

Field	Value	Cited text
Known as	Pyrazinamide	“This two-stage study will compare consented research participants with tuberculous meningitis receiving experimental Bedaquiline (B), Pretomanid (Pa), Linezolid (L);...” NCT07227779 ↗ 139 “anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS],...” NCT02365623 ↗ “INTERVENTIONS: Patients were randomized to receive daily treatment with 4 drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) given as an FDC (n = 798 patients) or...” PMID 21486974 ↗ Apr 2011 “This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol...” NCT06224036 ↗ “Experimental arms are seven oral regimens with a five-drug combination of the following: bedaquiline, linezolid, a fluoroquinolone (moxifloxacin or levofloxacin), cycloserine,...” NCT05081401 ↗ “FDC intensive phase containing 150 mg of rifampicin, 75 mg of isoniazid not 300mg, 400 mg of pyrazinamide, and 275 mg of ethambutol, while FDC continuation phase containing...” NCT05005637 ↗ “The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.” NCT03561753 ↗ “This study aimed to quantify the influence of food on the pharmacokinetics of isoniazid, rifampicin, ethambutol and pyrazinamide in TB patients starting anti-TB treatment.” PMID 26661397 ↗ Dec 2015 “SOC plus 6 months of tuberculosis treatment (isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, plus isoniazid and rifampicin for 4 subsequent months)” PMID 42468541 ↗ Jul 2026 “The investigational MDR-END Plus regimen consists of oral anti-tuberculosis drugs including bedaquiline, delamanid, delpazolid, levofloxacin, and pyrazinamide.” NCT07675954 ↗ “RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months” NCT04117698 ↗ Show 129 more sources
Known as	.alpha.-pyrazinamide	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Aldinamid	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Aldinamide	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Eprazin	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Farmizina	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Isopas	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	MK-56	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Novamid	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	NSC-14911	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Pirazimida	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Pirazinamid	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Pirazinamida	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Pirilene	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Pyrafat	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Pyramizade	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Pyrazide	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Pyrazinamide (Z)	“Pyrazinamide (Z)” NCT07656012 ↗
Known as	Pyrazinamide component of rifater	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	pyrazinamide tablets	“pyrazinamide tablets” NCT02331823 ↗
Known as	Pyrazinamidum	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Pyrazine carboxylamide	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	PYZ	“AI-optimised combination drug regimen consisting of Pyrazinamide (PYZ) and Hydroxychloroquine (HCQ) for treating drug-sensitive pulmonary tuberculosis.” NCT07467252 ↗
Known as	PZA	“Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are...” NCT00816426 ↗ 11 “Arm 1 participants will receive high-dose rifampicin for 8 weeks plus ethambutol at standard doses, in addition to standard doze pyrazinamide (PZA) and isoniazid.” NCT02958709 ↗ “The abbreviation of the name of the 3 drugs in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）” NCT03830671 ↗ “pyrazinamide (PZA, Z) is also essential in the treatment of multidrug-resistant (MDR)-TB.” PMID 26038418 ↗ Jul 2012 “Coadministering pyrazinamide (PZA) with the xanthine oxidase inhibitor” PMID 28739782 ↗ Sep 2017 “regimen of rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB)” PMID 24903795 ↗ May 2014 “Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd” NCT02128308 ↗ “Drug: Pyrazinamide (PZA)” NCT05383742 ↗ “pyrazinamide (PZA \[Z\])” NCT02371681 ↗ “pyrazinamide (Z / PZA)” NCT02231229 ↗ “Pyrazinamide (PZA):” NCT07268664 ↗ Show 1 more source
Known as	Rozide	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Tebrazid	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Unipyranamide	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Known as	Zinamide	ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗
Action	Inhibit	“PZA acts differently from common antibiotics by inhibiting multiple targets such as energy production, trans-translation, and perhaps pantothenate/coenzyme A required for...” PMID 26104205 ↗ Aug 2014
Modality	Small molecule	“is a synthetic derivative of nicotinamide” NCT00816426 ↗
Route	Oral	“Pyrazinamide (PZA) will be dosed orally” NCT00816426 ↗